N-terminal 6His-tagged recombinant human Abl, residues 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125).
Product Source: Expressed by baculovirus in Sf21 insect cells.
Research Sub Category
Protein Target: Abl
Target Sub-Family: TK
Routinely evaluated by phosphorylation of 50 μM Abltide. Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μg of active Abl (Q252H).
Specific Activity: one unit of Abl (Q252H) activity is defined as 1 nmol phosphate incorporated into 50 μM Abltide (EAIYAAPFAKKK) per minute at 30°C with a final ATP concentration of 100 μM.
10 μg of enzyme in 100 μL of 50 mM Tris/HCl pH7.5, 150 mM NaCl, 270 mM sucrose, 1 mM benzamidine, 0.2 mM PMSF, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij 35. Frozen solution.
Store -70°C. For maximum recovery of product, centrifuge original vial prior to removing the cap.
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.